Full-Time

Lead Architect

Posted on 12/13/2025

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Pune, Maharashtra, India + 1 more

More locations: Sant Cugat del Vallès, Barcelona, Spain

In Person

Category
Data & Analytics (2)
,
Requirements
  • BS in computer science, computer engineering, electrical engineering, or a related discipline. Master’s degree preferred.
  • 15+ years of hands-on coding experience (or equivalent).
  • Proven expertise in leading and mentoring principal software engineers and other junior software engineers.
  • Deep understanding of data warehousing, ETL processes, and data lake concepts.
  • Experience in real-time data streaming and processing frameworks (e.g., Kafka, Spark).
  • Knowledge of data governance, data quality, and data security best practices.
  • Experience in Data Analytics, Machine Learning, and generative AI.
  • Proficiency in cloud distribution/computing (Amazon Web Services), API Design, Data Modeling, Capacity Planning, and engineering best practices such as Test-Driven Development and Continuous Integration/Continuous Deployment.
  • Extensive experience in architecting and developing large-scale designs.
  • Solid experience in Agile methodologies for both delivery and operations.
  • Skilled in SQS, No-SQL technologies like PostgreSQL, Redis, DynamoDB, MongoDB.
  • Experience in Client-Service architecture, design patterns, and building cloud/enterprise-grade solutions.
  • Master’s degree preferred.
Responsibilities
  • Architecture Design and Development: Develop high-level and low-level design components, ensuring scalability, supportability, and extensibility of software products.
  • Drive software architecture that can be adaptable to support healthcare software products in the cloud across several clinical domains.
  • Define the technology roadmap, focusing on data aspects such as data ingestion pipelines (batch, streaming), data storage solutions (SQL, NoSQL, Data Lakes), data transformation and processing frameworks, data quality and governance tools, data cataloging and metadata management, and data visualization and reporting tools.
  • Leadership: Lead other architects and senior engineers to design, plan, deliver, and operate the data platform.
  • Provide leadership in project execution by defining incremental design improvements that can continuously evolve the platform, mitigate project risks, and continuously deliver additional stakeholder value.
  • Scope and define proof-of-concepts, including identifying technology options and assessments.
  • Provide technical leadership to the product teams to help their products with the data platform.
  • Collaboration: Collaborate with various groups like Product Management, UX, Customer Success, Sales, Compliance, Legal, and more to understand and meet customer needs.
  • Communicate with stakeholders including customers to explain solutions and technology, obtain customer insights, and translate them into technical deliverables.
  • Quality Assurance: Ensure high quality software that is highly scalable, available, reliable, supportable, and extensible and integrates with other Roche products and platforms.
  • Leadership Skills: Build and provide effective technical leadership for a global team, inspire and lead project teams to create transformative solutions, influence uptake in the wider organization, and ensure customer solutions are at the forefront of Data Platform & Insights Services and deliver its optimal contribution to the Roche Diagnostics Vision.
Desired Qualifications
  • Master in CS, Engineering (preferred)
  • Experience in Healthcare tech, standards, and workflows (e.g. HL7, FHIR)
  • Experience with QMS for FDA-regulated products

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI can strengthen AI pathology workflows and biomarker discovery.
  • Elecsys pTau217 expands Roche's Alzheimer diagnostics beyond specialist laboratory settings.
  • Nurix collaboration deepens Roche's reach into protein degradation and hematology.

What critics are saying

  • Swiss franc strength keeps distorting reported growth and investor perception.
  • Patent expirations on older medicines force rapid replacement from newer assets.
  • CT-388 must beat Novo Nordisk and Eli Lilly to matter.

What makes Roche unique

  • Roche combines pharmaceuticals, diagnostics, and digital pathology across one healthcare platform.
  • Founded in Basel in 1896, Roche built scale through branded medicines.
  • Genentech integration made Roche the world's largest biotechnology company.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Roche who can refer or advise you

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE